[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Dopamine is combined with Antipyrine.]
[J01GA01, streptomycin, Dopamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01CG01, sulbactam, Dopamine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Dopamine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Dopamine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Dopamine is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Dopamine is combined with Mercaptopurine.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Terbutaline is combined with Dopamine.]
[B01AE07, dabigatran etexilate, Dopamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of hypertension can be increased when Dopamine is combined with Lurasidone.]
[A04AD10, dronabinol, The risk or severity of Tachycardia can be increased when Dronabinol is combined with Dopamine.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Dopamine is combined with Theobromine.]
[R03DA04, theophylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Theophylline.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[A11DA01, thiamine, The serum concentration of Dopamine can be increased when it is combined with Thiamine.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AB08, thioproperazine, The risk or severity of hypertension can be increased when Dopamine is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of hypertension can be increased when Thioridazine is combined with Dopamine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Dopamine is combined with Moxisylyte.]
[V04CJ01, thyrotropin, The risk or severity of adverse effects can be increased when Dopamine is combined with Thyrotropin.]
[V04CJ02, thyrotropin-releasing hormone, The risk or severity of adverse effects can be increased when Dopamine is combined with Protirelin.]
[N05AL03, tiapride, Dopamine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S01ED01, timolol, Dopamine may decrease the antihypertensive activities of Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S01AA12, tobramycin, Dopamine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M02AX02, tolazoline, Dopamine may decrease the antihypertensive activities of Tolazoline.]
[V04CA01, tolbutamide, Dopamine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Dopamine.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AF04, tranylcypromine, The metabolism of Dopamine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of hypertension can be increased when Trazodone is combined with Dopamine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Dopamine is combined with Mepenzolate.]
[A16AX12, trientine, Dopamine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Dopamine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Dopamine.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Dopamine.]
[A03AA05, trimebutine, Dopamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[C02BA01, trimethaphan, Dopamine may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The serum concentration of Dopamine can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of hypertension can be increased when Trimipramine is combined with Dopamine.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Dopamine is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Dopamine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[R03DX07, roflumilast, Dopamine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Dopamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The serum concentration of Dopamine can be increased when it is combined with Vandetanib.]
[R02AA14, oxyquinoline, Dopamine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The serum concentration of Linagliptin can be increased when it is combined with Dopamine.]
[S01AA28, vancomycin, Dopamine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Dopamine may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Dopamine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Dopamine is combined with Indacaterol.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Dopamine.]
[N06AX09, viloxazine, Dopamine may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[C04AX07, vincamine, Dopamine may decrease the antihypertensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[B01AA03, warfarin, Dopamine may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[N01AX15, xenon, Xenon may increase the arrhythmogenic activities of Dopamine.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of hypertension can be increased when Dopamine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Dopamine.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Dopamine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Dopamine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The serum concentration of Dopamine can be increased when it is combined with Crizotinib.]
[A02BC04, rabeprazole, Dopamine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Dopamine.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Dopamine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Dopamine.]
[L01EJ01, ruxolitinib, Dopamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Dopamine may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Dopamine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Dopamine may decrease the antihypertensive activities of Atenolol.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Atropine is combined with Dopamine.]
[M01CB03, auranofin, Dopamine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Dopamine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L04AX01, azathioprine, Dopamine may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[A08AA11, lorcaserin, Dopamine may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Dopamine is combined with Mirabegron.]
[L02BB04, enzalutamide, Dopamine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Octopamine.]
[D02BA02, octinoxate, Dopamine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of adverse effects can be increased when Nelfinavir is combined with Dopamine.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Dopamine is combined with Rasagiline.]
[C08CA13, lercanidipine, Dopamine may decrease the antihypertensive activities of Lercanidipine.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Dopamine.]
[R06AC06, thonzylamine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of Tachycardia can be increased when Darifenacin is combined with Dopamine.]
[V09IX04, fluorodeoxyglucose F18, Dopamine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, Diethyl ether may increase the arrhythmogenic activities of Dopamine.]
[V08CA11, gadofosveset, Dopamine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Dopamine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Dopamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Dopamine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Dopamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Dopamine is combined with Benorilate.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[H03AA04, tiratricol, The risk or severity of adverse effects can be increased when Dopamine is combined with Tiratricol.]
[L03AA12, ancestim, Dopamine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Dopamine.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Naratriptan is combined with Dopamine.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Dopamine can be increased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Dopamine is combined with Benzydamine.]
[L01EE01, trametinib, Dopamine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Dopamine is combined with Parathyroid hormone.]
[V09AX05, florbetapir F-18, Dopamine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, Dopamine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AJ03, dolutegravir, The serum concentration of Dopamine can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, Dopamine may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Dopamine may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, Dopamine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Dopamine may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Dopamine is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J05AP08, sofosbuvir, Dopamine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, The therapeutic efficacy of Dopamine can be increased when used in combination with Droxidopa.]
[C07AB04, acebutolol, Dopamine may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, Dopamine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Dopamine may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Dopamine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S01ED02, betaxolol, Dopamine may decrease the antihypertensive activities of Betaxolol.]
[V03AB34, fomepizole, Dopamine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Dopamine may decrease the antihypertensive activities of Bethanidine.]
[A03BA03, hyoscyamine, The risk or severity of Tachycardia can be increased when Hyoscyamine is combined with Dopamine.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Dopamine is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Dopamine.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of hypertension can be increased when Dopamine is combined with Acepromazine.]
[N04AA02, biperiden, The risk or severity of Tachycardia can be increased when Biperiden is combined with Dopamine.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Dopamine.]
[B01AF03, edoxaban, Dopamine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of hypertension can be increased when Mirtazapine is combined with Dopamine.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Dopamine.]
[L01EX08, lenvatinib, The serum concentration of Dopamine can be increased when it is combined with Lenvatinib.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Difemerine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AX16, brexpiprazole, The risk or severity of hypertension can be increased when Dopamine is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Dopamine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Dopamine is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Dopamine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Dopamine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB37, idarucizumab, Dopamine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The serum concentration of Dopamine can be increased when it is combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dopamine.]
[L01XG03, ixazomib, Dopamine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Dopamine may decrease the antihypertensive activities of Selexipag.]
[M04AB05, lesinurad, Dopamine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Dopamine is combined with Alminoprofen.]
[N03AX23, brivaracetam, Dopamine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Dopamine may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypertension can be increased when Dopamine is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Dopamine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[R06AB01, brompheniramine, The risk or severity of Tachycardia can be increased when Brompheniramine is combined with Dopamine.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Dopamine is combined with Amineptine.]
[C08CA01, amlodipine, Dopamine may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Dopamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, Dopamine may decrease the antihypertensive activities of Bupranolol.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Buspirone is combined with Dopamine.]
[L01XX27, arsenic trioxide, Dopamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Dopamine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Dopamine is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Dopamine is combined with Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Bamifylline.]
[A06AH05, naldemedine, Dopamine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Dopamine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Dopamine is combined with Caffeine.]
[C09AA07, benazepril, Dopamine may decrease the antihypertensive activities of Benazepril.]
[P01CA02, benznidazole, Dopamine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Dopamine.]
[J05AF06, abacavir, Dopamine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[H03BA03, benzylthiouracil, The risk or severity of adverse effects can be increased when Dopamine is combined with Benzylthiouracil.]
[N07XX13, valbenazine, Dopamine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[H05AA04, abaloparatide, The risk or severity of adverse effects can be increased when Dopamine is combined with Abaloparatide.]
[N04BD03, safinamide, The metabolism of Dopamine can be decreased when combined with Safinamide.]
[J01MA23, delafloxacin, Dopamine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Dopamine may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The serum concentration of Dopamine can be increased when it is combined with Enasidenib.]
[C07AB07, bisoprolol, Dopamine may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Bitolterol is combined with Dopamine.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Dopamine.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Bornaprine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Dopamine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Dopamine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Dopamine is combined with Bumadizone.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Dopamine is combined with Butriptyline.]
[N01BX04, capsaicin, The metabolism of Dopamine can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Dopamine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Dopamine may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The serum concentration of Dopamine can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, Dopamine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Camylofin.]
[H03BB01, carbimazole, The risk or severity of adverse effects can be increased when Dopamine is combined with Carbimazole.]
[C07AG02, carvedilol, Dopamine may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of hypertension can be increased when Dopamine is combined with Cannabidiol.]
[L04AA37, baricitinib, Dopamine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01GB14, plazomicin, Dopamine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Dopamine may decrease the antihypertensive activities of Celiprolol.]
[P01BA07, tafenoquine, The serum concentration of Dopamine can be increased when it is combined with Tafenoquine.]
[A16AX14, migalastat, Dopamine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Dopamine may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Dopamine.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[D08AE05, chloroxylenol, Dopamine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Dopamine is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Oxtriphylline.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Dopamine.]
[A06AX05, prucalopride, Dopamine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Dopamine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, Dopamine may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Dopamine is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Dopamine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Dopamine is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Dopamine.]
[L01EN01, erdafitinib, The serum concentration of Dopamine can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C09CA06, candesartan, Dopamine may decrease the antihypertensive activities of Candesartan.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Pitolisant is combined with Dopamine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Dopamine is combined with Yohimbine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M09AX08, golodirsen, Dopamine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Dopamine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Dopamine is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dopamine is combined with Dutasteride.]
[R02AA03, dichlorobenzyl alcohol, Dopamine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Dopamine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Dopamine.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Dopamine.]
[C08CA16, clevidipine, Dopamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The serum concentration of Dopamine can be increased when it is combined with Dronedarone.]
[C02AA06, methoserpidine, Dopamine may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The serum concentration of Dopamine can be increased when it is combined with Tucatinib.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Dihexyverine.]
[N04BX04, opicapone, The metabolism of Dopamine can be decreased when combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Dopamine is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of Tachycardia can be increased when Trospium is combined with Dopamine.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Dopamine is combined with Droxicam.]
[V08CA05, mangafodipir, Dopamine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Dopamine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Dopamine is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Dopamine may decrease the antihypertensive activities of Levamlodipine.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The serum concentration of Dopamine can be increased when it is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of hypertension can be increased when Chlorpromazine is combined with Dopamine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of Tachycardia can be increased when Dopamine is combined with Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Dopamine is combined with Ethenzamide.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Dopamine.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Dopamine.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Dopamine is combined with Etofenamate.]
[M01AX25, chondroitin sulfates, Dopamine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Dopamine is combined with Naxitamab.]
[V03AF12, trilaciclib, The serum concentration of Dopamine can be increased when it is combined with Trilaciclib.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Dopamine is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Fenethylline.]
[C01CA19, fenoldopam, Dopamine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Dopamine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Dopamine is combined with Finasteride.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N02BG07, flupirtine, Dopamine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of adverse effects can be increased when Formoterol is combined with Dopamine.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the arrhythmogenic activities of Dopamine.]
[H04AA02, dasiglucagon, Dopamine may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The risk or severity of adverse effects can be increased when Dopamine is combined with Follitropin.]
[A02BA01, cimetidine, The serum concentration of Dopamine can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L01XA01, cisplatin, The serum concentration of Cisplatin can be increased when it is combined with Dopamine.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The serum concentration of Dopamine can be increased when it is combined with Fexinidazole.]
[V09AB03, ioflupane I-123, Dopamine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Dopamine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Dopamine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Dopamine is combined with Clenbuterol.]
[N01BB10, levobupivacaine, Dopamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The serum concentration of Dopamine can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of hypertension can be increased when Dopamine is combined with Clomipramine.]
[N03AE01, clonazepam, Dopamine may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, Dopamine may decrease the antihypertensive activities of Clonidine.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH02, clozapine, The risk or severity of hypertension can be increased when Clozapine is combined with Dopamine.]
[J01GB12, arbekacin, Dopamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of Tachycardia can be increased when Cocaine is combined with Dopamine.]
[C02KB01, metyrosine, Dopamine may decrease the antihypertensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Dopamine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Dopamine.]
[M04AC01, colchicine, Dopamine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Dopamine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Homatropine methylbromide is combined with Dopamine.]
[J01XB01, colistin, Dopamine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N01AB07, desflurane, Desflurane may increase the arrhythmogenic activities of Dopamine.]
[A04AA03, tropisetron, Dopamine may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Dopamine is combined with Ifenprodil.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Dopamine is combined with Imidazole salicylate.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Dopamine is combined with Indobufen.]
[J05AB14, valganciclovir, Dopamine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Dopamine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Dopamine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Dopamine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Dopamine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Dopamine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Dopamine.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Dopamine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Almotriptan is combined with Dopamine.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Dopamine is combined with Parecoxib.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Dopamine.]
[N05BA10, ketazolam, Dopamine may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Dopamine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Dopamine can be increased when it is combined with Imatinib.]
[C08CA09, lacidipine, Dopamine may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, The serum concentration of Dopamine can be increased when it is combined with Lamotrigine.]
[N07BC04, lofexidine, Dopamine may decrease the antihypertensive activities of Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Dopamine is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Dopamine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C09AA03, lisinopril, Dopamine may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Dopamine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Dopamine may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Dopamine is combined with Mefenorex.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dopamine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Dopamine.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Dopamine is combined with Methoxyphenamine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Dopamine may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AX07, minaprine, The metabolism of Dopamine can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Dopamine.]
[N06AG02, moclobemide, The metabolism of Dopamine can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of Tachycardia can be increased when Cyproheptadine is combined with Dopamine.]
[C09AA13, moexipril, Dopamine may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Dopamine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Dopamine is combined with Morniflumate.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, Dopamine may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Dopamine is combined with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C02CC04, debrisoquin, Dopamine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Dopamine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Dopamine.]
[N07BB05, nalmefene, Dopamine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, Dopamine may decrease the antihypertensive activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of hypertension can be increased when Dopamine is combined with Nefazodone.]
[C01DX16, nicorandil, Dopamine may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01CA23, theodrenaline, The therapeutic efficacy of Dopamine can be increased when used in combination with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Dopamine is combined with Norfenefrine.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Dopamine is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Dopamine is combined with Olsalazine.]
[N06AA01, desipramine, The serum concentration of Dopamine can be increased when it is combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Dopamine.]
[V04CH02, indigo carmine, Dopamine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C09XA02, aliskiren, Dopamine may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The serum concentration of Oxaliplatin can be increased when it is combined with Dopamine.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Dopamine is combined with Oxaprozin.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Dopamine is combined with Dexetimide.]
[G04BD04, oxybutynin, The risk or severity of Tachycardia can be increased when Dopamine is combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Dopamine.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Dopamine.]
[H05AA02, teriparatide, The risk or severity of adverse effects can be increased when Dopamine is combined with Teriparatide.]
[N06AB05, paroxetine, The risk or severity of Tachycardia can be increased when Paroxetine is combined with Dopamine.]
[B01AC04, clopidogrel, The serum concentration of Dopamine can be increased when it is combined with Clopidogrel.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Pentifylline.]
[P03AC04, permethrin, Dopamine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[V03AH01, diazoxide, Dopamine may decrease the antihypertensive activities of Diazoxide.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Dopamine is combined with Dibenzepin.]
[R05DA08, pholcodine, Dopamine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Dopamine.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C02DG01, pinacidil, Dopamine may decrease the antihypertensive activities of Pinacidil.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Dopamine is combined with Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Dopamine is combined with Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Diethylpropion is combined with Dopamine.]
[C08CA03, isradipine, Dopamine may decrease the antihypertensive activities of Isradipine.]
[D07XC04, diflucortolone, Dopamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Dopamine.]
[C01AA05, digoxin, Dopamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Dopamine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Dopamine is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Dopamine.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[B01AC21, treprostinil, Dopamine may decrease the antihypertensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, The risk or severity of adverse effects can be increased when Dopamine is combined with Potassium perchlorate.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C08DB01, diltiazem, Dopamine may decrease the antihypertensive activities of Diltiazem.]
[V03AB09, dimercaprol, Dopamine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R06AB03, dimethindene, The risk or severity of Tachycardia can be increased when Dopamine is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Dopamine is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, Dopamine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Propentofylline.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Dopamine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Dopamine is combined with Proglumetacin.]
[G02AD02, dinoprostone, The serum concentration of Dopamine can be increased when it is combined with Dinoprostone.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Proxyphylline.]
[R06AA02, diphenhydramine, The serum concentration of Dopamine can be increased when it is combined with Diphenhydramine.]
[C09AA06, quinapril, Dopamine may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Dopamine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Dopamine is combined with Quinupramine.]
[C09AA05, ramipril, Dopamine may decrease the antihypertensive activities of Ramipril.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Dopamine is combined with Reproterol.]
[S01AX06, resorcinol, Dopamine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The serum concentration of Dopamine can be increased when it is combined with Disopyramide.]
[N05AX08, risperidone, The risk or severity of hypertension can be increased when Risperidone is combined with Dopamine.]
[R06AE09, levocetirizine, Dopamine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, Ropivacaine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE08, tadalafil, Dopamine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Dopamine.]
[C02KX02, ambrisentan, Dopamine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Dopamine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Dopamine is combined with Salsalate.]
[R03AC12, salmeterol, The serum concentration of Dopamine can be increased when it is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of adverse effects can be increased when Dopamine is combined with Salmon calcitonin.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Dobutamine is combined with Dopamine.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Dopamine.]
[C01DA05, pentaerythritol tetranitrate, Dopamine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of hypertension can be increased when Dopamine is combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Dopamine.]
[N06AA12, doxepin, The risk or severity of hypertension can be increased when Dopamine is combined with Doxepin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of Tachycardia can be increased when Doxylamine is combined with Dopamine.]
[N01AB08, sevoflurane, Sevoflurane may increase the arrhythmogenic activities of Dopamine.]
[N05AD08, droperidol, The risk or severity of hypertension can be increased when Droperidol is combined with Dopamine.]
[A08AA10, sibutramine, Dopamine may decrease the excretion rate of Sibutramine which could result in a higher serum level.]
[A12CA02, sodium sulfate, Dopamine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Dopamine may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Dyphylline.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Dopamine.]
[V04CX07, edrophonium, Dopamine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, Dopamine may decrease the antihypertensive activities of Talinolol.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Dopamine.]
[G04CA03, terazosin, Dopamine may decrease the antihypertensive activities of Terazosin.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Dopamine is combined with Tetryzoline.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Dopamine is combined with Emepronium.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Dopamine is combined with Tianeptine.]
[C09AA02, enalapril, Dopamine may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Dopamine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The metabolism of Dopamine can be decreased when combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dopamine.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Dopamine is combined with Tramazoline.]
[C09AA10, trandolapril, Dopamine may decrease the antihypertensive activities of Trandolapril.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Dopamine.]
[G03GA05, follitropin alfa, The risk or severity of adverse effects can be increased when Dopamine is combined with Follitropin.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Dopamine is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the arrhythmogenic activities of Dopamine.]
[C02CA06, urapidil, Dopamine may decrease the antihypertensive activities of Urapidil.]
[S01FB02, ephedrine, The therapeutic efficacy of Dopamine can be increased when used in combination with Ephedrine.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Dopamine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Dopamine is combined with Xylometazoline.]
[S01EA01, epinephrine, The therapeutic efficacy of Dopamine can be increased when used in combination with Epinephrine.]
[C09AA15, zofenopril, Dopamine may decrease the antihypertensive activities of Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Dopamine is combined with Zomepirac.]
[N03AX15, zonisamide, The metabolism of Dopamine can be decreased when combined with Zonisamide.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Dopamine.]
[G02AB03, ergonovine, The risk or severity of hypertension can be increased when Dopamine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of hypertension can be increased when Dopamine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of hypertension can be increased when Ergotamine is combined with Dopamine.]
[L03AX05, pidotimod, Dopamine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, Dopamine may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[G03CA03, estradiol, The serum concentration of Dopamine can be increased when it is combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Dopamine is combined with Gepefrine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N04AA05, profenamine, The risk or severity of Tachycardia can be increased when Profenamine is combined with Dopamine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Dopamine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Dopamine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Dopamine.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[P01AX07, trimetrexate, Dopamine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The excretion of Dopamine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Dopamine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Dopamine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[A02BA03, famotidine, The serum concentration of Dopamine can be increased when it is combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C08CA02, felodipine, Dopamine may decrease the antihypertensive activities of Felodipine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Dopamine.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Dopamine is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Fentanyl is combined with Dopamine.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Dopamine is combined with Salbutamol.]
[L01BB06, clofarabine, The serum concentration of Clofarabine can be increased when it is combined with Dopamine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[G04BD02, flavoxate, Dopamine may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Dopamine is combined with Floctafenine.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J02AX01, flucytosine, Dopamine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Dopamine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Dopamine is combined with Melitracen.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AF01, flupenthixol, The risk or severity of hypertension can be increased when Flupentixol is combined with Dopamine.]
[N05CD01, flurazepam, The serum concentration of Dopamine can be increased when it is combined with Flurazepam.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Dopamine.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L01BC03, tegafur, Dopamine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Dopamine is combined with Adrafinil.]
[G01AX06, furazolidone, The metabolism of Dopamine can be decreased when combined with Furazolidone.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Ganciclovir is combined with Dopamine.]
[C10AB04, gemfibrozil, Dopamine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Dopamine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of hypertension can be increased when Cabergoline is combined with Dopamine.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Dopamine is combined with Cafedrine.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Alfentanil is combined with Dopamine.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Dopamine.]
[A10BB07, glipizide, Dopamine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Dexmedetomidine is combined with Dopamine.]
[C05AE01, nitroglycerin, Dopamine may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Dopamine.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Dopamine.]
[H01AB01, thyrotropin alfa, The risk or severity of adverse effects can be increased when Dopamine is combined with Thyrotropin alfa.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C07AB09, esmolol, Dopamine may decrease the antihypertensive activities of Esmolol.]
[M01CB04, aurothioglucose, Dopamine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Dopamine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Dopamine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Dopamine may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AD01, haloperidol, Haloperidol may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N01AB01, halothane, Halothane may increase the arrhythmogenic activities of Dopamine.]
[N05AH04, quetiapine, The risk or severity of hypertension can be increased when Dopamine is combined with Quetiapine.]
[N06BX13, idebenone, Dopamine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C09CA01, losartan, Dopamine may decrease the antihypertensive activities of Losartan.]
[G03DC01, allylestrenol, Dopamine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dopamine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Dopamine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Dopamine.]
[C08CA10, nilvadipine, Dopamine may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Dopamine is combined with Nimesulide.]
[C09AA04, perindopril, Dopamine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Dopamine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Dopamine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypertension can be increased when Dopamine is combined with Propiverine.]
[B05AA07, hetastarch, Dopamine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[C02AC06, rilmenidine, Dopamine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Dopamine is combined with Ibuprofen.]
[B05XA08, sodium acetate, Dopamine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Dopamine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Sufentanil is combined with Dopamine.]
[N06AA02, imipramine, The serum concentration of Dopamine can be increased when it is combined with Imipramine.]
[R01AD07, tixocortol, Dopamine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of Tachycardia can be increased when Tizanidine is combined with Dopamine.]
[L01CE01, topotecan, Dopamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Dopamine.]
[C02CA02, indoramin, Dopamine may decrease the antihypertensive activities of Indoramin.]
[A11HA07, inositol, Dopamine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Dopamine may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Dopamine is combined with Piperidolate.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Dopamine.]
[A10BH01, sitagliptin, Dopamine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of Tachycardia can be increased when Buclizine is combined with Dopamine.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Dopamine.]
[C07AA01, alprenolol, Dopamine may decrease the antihypertensive activities of Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Dopamine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Dopamine is combined with Iprindole.]
[N06AF05, iproniazid, The metabolism of Dopamine can be decreased when combined with Iproniazid.]
[N06AF01, isocarboxazid, The metabolism of Dopamine can be decreased when combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Dopamine.]
[C09AA16, imidapril, Dopamine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the arrhythmogenic activities of Dopamine.]
[N04BX02, entacapone, The metabolism of Dopamine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J05AX05, inosine pranobex, Dopamine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Dopamine is combined with Isoprenaline.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Dopamine is combined with Isoxsuprine.]
[S01AA24, kanamycin, Dopamine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, Dopamine may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, Dopamine may decrease the antihypertensive activities of Ketanserin.]
[B01AC22, prasugrel, Dopamine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[N05AH03, olanzapine, The risk or severity of Tachycardia can be increased when Olanzapine is combined with Dopamine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Dopamine is combined with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Dopamine is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Dopamine is combined with Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Dopamine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Dopamine may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, The serum concentration of Dopamine can be increased when it is combined with Amantadine.]
[C02AA05, deserpidine, Dopamine may decrease the antihypertensive activities of Deserpidine.]
[A06AX03, lubiprostone, Dopamine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA21, amikacin, Dopamine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, The serum concentration of Dopamine can be increased when it is combined with Amiloride.]
[N02CA07, lisuride, The risk or severity of hypertension can be increased when Lisuride is combined with Dopamine.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Dopamine is combined with Lofepramine.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[B05XA11, magnesium chloride, Dopamine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Dopamine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, Dopamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Dopamine.]
[C02BB01, mecamylamine, Dopamine may decrease the antihypertensive activities of Mecamylamine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Dopamine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Dopamine.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Dopamine is combined with Mephentermine.]
[N01BB03, mepivacaine, Mepivacaine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[G04BX16, tiopronin, Dopamine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, The risk or severity of hypertension can be increased when Dopamine is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Dopamine.]
[A10BA02, metformin, The serum concentration of Dopamine can be increased when it is combined with Metformin.]
[N07BC02, methadone, Methadone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06BA03, methamphetamine, The metabolism of Dopamine can be decreased when combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Methantheline is combined with Dopamine.]
[J05AF05, lamivudine, The serum concentration of Lamivudine can be increased when it is combined with Dopamine.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Dopamine is combined with Metergoline.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Dopamine is combined with Methimazole.]
[L01BA04, pemetrexed, Dopamine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The risk or severity of hypertension can be increased when Dopamine is combined with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Dopamine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the arrhythmogenic activities of Dopamine.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Dopamine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, The serum concentration of Dopamine can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Dopamine.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Dopamine.]
[G03EK01, methyltestosterone, Dopamine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Dopamine.]
[A03FA01, metoclopramide, Dopamine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The serum concentration of Dopamine can be increased when it is combined with Metoprolol.]
[V04CD01, metyrapone, Dopamine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Dopamine is combined with Mianserin.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Dopamine is combined with Aminophenazone.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Dopamine.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C09CA03, valsartan, Dopamine may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Dopamine may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Dopamine is combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01BD01, amiodarone, The serum concentration of Dopamine can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of hypertension can be increased when Amitriptyline is combined with Dopamine.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Dopamine may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Dopamine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Dopamine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N06AA17, amoxapine, The risk or severity of hypertension can be increased when Amoxapine is combined with Dopamine.]
[N03AB05, fosphenytoin, The risk or severity of hypotension can be increased when Fosphenytoin is combined with Dopamine.]
[C07AA12, nadolol, Dopamine may decrease the antihypertensive activities of Nadolol.]
[J01CA04, amoxicillin, Dopamine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Dopamine may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Dopamine is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Dopamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Dopamine.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N04BX01, tolcapone, The metabolism of Dopamine can be decreased when combined with Tolcapone.]
[S03AA01, neomycin, Dopamine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Remifentanil is combined with Dopamine.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of hypertension can be increased when Dopamine is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L03AX16, plerixafor, Dopamine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Dopamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Dopamine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[C09CA07, telmisartan, Dopamine may decrease the antihypertensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C01CE01, inamrinone, Dopamine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Dopamine is combined with Nialamide.]
[C08CA04, nicardipine, Dopamine may decrease the antihypertensive activities of Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Dopamine.]
[N07BA01, nicotine, The metabolism of Dopamine can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, Dopamine may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Dopamine is combined with Niflumic acid.]
[C08CA06, nimodipine, Dopamine may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Dopamine may decrease the antihypertensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Dopamine may decrease the antihypertensive activities of Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Dopamine.]
[C02DD01, nitroprusside, Dopamine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the arrhythmogenic activities of Dopamine.]
[C01CA03, norepinephrine, The therapeutic efficacy of Dopamine can be increased when used in combination with Norepinephrine.]
[C02KX01, bosentan, Dopamine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The risk or severity of hypertension can be increased when Nortriptyline is combined with Dopamine.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Dopamine is combined with Nylidrin.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Dopamine is combined with Opipramol.]
[N02AA02, opium, Dopamine may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Dopamine.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C07AA02, oxprenolol, The serum concentration of Dopamine can be increased when it is combined with Oxprenolol.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Dopamine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Dopamine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Dopamine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Dopamine.]
[V04CH30, 4-aminohippuric acid, The serum concentration of Dopamine can be increased when it is combined with Aminohippuric acid.]
[N05AH05, asenapine, The risk or severity of hypertension can be increased when Dopamine is combined with Asenapine.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Dopamine.]
[J04AB30, capreomycin, Dopamine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[C02KC01, pargyline, The metabolism of Dopamine can be decreased when combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[G04BD11, fesoterodine, Dopamine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Dopamine may decrease the antihypertensive activities of Penbutolol.]
[J01CE09, penicillin G procaine, Dopamine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[L01XX08, pentostatin, Dopamine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Dopamine is combined with Pentoxifylline.]
[N04BC02, pergolide, The risk or severity of hypertension can be increased when Dopamine is combined with Pergolide.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Phenelzine is combined with Dopamine.]
[A10BA01, phenformin, The serum concentration of Dopamine can be increased when it is combined with Phenformin.]
[C04AX02, phenoxybenzamine, The serum concentration of Dopamine can be increased when it is combined with Phenoxybenzamine.]
[A08AA01, phentermine, The metabolism of Dopamine can be decreased when combined with Phentermine.]
[V03AB36, phentolamine, Dopamine may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Dopamine.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Dopamine.]
[R01BA01, phenylpropanolamine, The metabolism of Dopamine can be decreased when combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The risk or severity of hypotension can be increased when Phenytoin is combined with Dopamine.]
[S01AE05, levofloxacin, Dopamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Dopamine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C08CX01, mibefradil, Dopamine may decrease the antihypertensive activities of Mibefradil.]
[C07AA03, pindolol, Dopamine may decrease the antihypertensive activities of Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of adverse effects can be increased when Saquinavir is combined with Dopamine.]
[N06BX03, piracetam, Dopamine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Dopamine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Pirenzepine is combined with Dopamine.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Dopamine.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[J01MA11, grepafloxacin, The serum concentration of Dopamine can be increased when it is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of hypertension can be increased when Dopamine is combined with Pizotifen.]
[C09CA04, irbesartan, Dopamine may decrease the antihypertensive activities of Irbesartan.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH03, saxagliptin, Dopamine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[V03AB21, potassium iodide, The risk or severity of adverse effects can be increased when Dopamine is combined with Potassium Iodide.]
[C07AB01, practolol, Dopamine may decrease the antihypertensive activities of Practolol.]
[C02CA01, prazosin, The serum concentration of Prazosin can be increased when it is combined with Dopamine.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[M04AB01, probenecid, The serum concentration of Dopamine can be increased when it is combined with Probenecid.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Dopamine.]
[C10AB05, fenofibrate, Dopamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Procyclidine is combined with Dopamine.]
[G03DA04, progesterone, The serum concentration of Dopamine can be increased when it is combined with Progesterone.]
[N05AA03, promazine, The risk or severity of hypertension can be increased when Promazine is combined with Dopamine.]
[R06AD02, promethazine, Dopamine may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[C01BC03, propafenone, The risk or severity of hypertension can be increased when Dopamine is combined with Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N05AC01, periciazine, The risk or severity of hypertension can be increased when Dopamine is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hypertension can be increased when Propiomazine is combined with Dopamine.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Propofol is combined with Dopamine.]
[C07AA05, propranolol, The metabolism of Dopamine can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Dopamine is combined with Propylthiouracil.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Rizatriptan is combined with Dopamine.]
[B01AC09, epoprostenol, Dopamine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Dopamine.]
[R01BA02, pseudoephedrine, The metabolism of Dopamine can be decreased when combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of hypertension can be increased when Dopamine is combined with Aripiprazole.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Dopamine.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Dopamine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Dopamine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Dopamine is combined with Methscopolamine.]
[P02CC01, pyrantel, Dopamine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[P01AX05, quinacrine, The serum concentration of Dopamine can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, Dopamine may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The serum concentration of Dopamine can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Dopamine can be increased when it is combined with Ranitidine.]
[C02AA01, rescinnamine, Dopamine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Reserpine can be increased when it is combined with Dopamine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Dopamine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Ritodrine is combined with Dopamine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Dopamine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Dopamine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Dopamine.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Dopamine.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N04BD01, selegiline, The metabolism of Dopamine can be decreased when combined with Selegiline.]
[J01GB08, sisomicin, Dopamine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Dopamine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Dopamine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Dopamine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[C01DA14, isosorbide mononitrate, Dopamine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[H02CA04, levoketoconazole, The serum concentration of Dopamine can be increased when it is combined with Levoketoconazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Dopamine.]
